Neumora Therapeutics (NMRA)

• Market cap: $280M
• 1 day: -1.31%
• 5 days: -15.17%
• 1 month: -14.69%
• 3 months: -42.8%
• 6 months: -12.21%
• Year to date: -9.04%
• 1 year: 93.59%
• 5 years: -90.71%
• 10 years: -90.71%
• Sector: Healthcare
• Industry: Biotechnology

About: Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.

Employees: 92